GlobeNewswire

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

Share
  • C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3
  • Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the complement system’s alternative pathway, targeting the underlying cause of C3G.4–6
  • Data presented at the American Society of Nephrology (ASN) 2020 Annual Meeting shows that investigational iptacopan effectively and safely reduced proteinuria in patients with C3G7.
  • Iptacopan is in parallel development for a number of renal conditions, including C3 glomerulopathy (C3G), IgA nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and membranous nephropathy (iMN) as well as in paroxysmal nocturnal hemoglobinuria (PNH), a hematological disease. Positive Phase II results in PNH were presented at EBMT in August8.
  • The European Medicines Agency has granted iptacopan a priority medicines (PRIME) designation in C3G and an orphan drug designation in IgA nephropathy (IgAN).

Basel, October 26, 2020 — Novartis today announced positive Phase II interim analysis results for iptacopan (LNP023), an investigational oral treatment for C3 glomerulopathy (C3G), presented at the virtually held American Society of Nephrology (ASN) 2020 Annual Meeting.

Data from the open-label Phase II study (NCT03832114), showed that after 12 weeks, iptacopan significantly reduced proteinuria by 49% compared to baseline values, as measured by 24-hour urine protein/creatinine ratio (UPCR) assessment, in twelve patients with C3G (P=0.0005). Iptacopan strongly inhibited alternative complement pathway activity and improved plasma C3 levels. In addition, iptacopan stabilized renal function as assessed by eGFR (estimated glomerular filtration rate) at week 12 and this effect was maintained in the seven patients that were treated for a total of six months after rolling over into the long-term extension study (NCT03955445)7.

“Proteinuria indicates the presence of inflammation in the kidney. Results from this study demonstrate that iptacopan significantly reduces proteinuria in patients with C3G,” said the lead study investigator, Dr Edwin Wong, Consultant Nephrologist at the National Renal Complement Therapeutics Centre, Newcastle upon Tyne NHS Foundation Trust, Newcastle University. “This data also highlights iptacopan’s ability to strongly and specifically inhibit the alternative complement pathway, targeting the underlying cause of this disease and potentially providing a much needed treatment option for C3G patients who have significant unmet needs.”

Iptacopan also had a favorable safety and tolerability profile in this Phase II study with no deaths, no serious adverse events suspected to be related to iptacopan and no adverse events leading to treatment discontinuation.

“Iptacopan is the most advanced asset in our nephrology pipeline.” said John Tsai, Head Global Drug Development and Chief Medical Officer at Novartis. “These data demonstrate that it has the potential to improve the lives of patients with C3G.”

The European Medicines Agency (EMA) has granted PRIME designation for iptacopan in C3G. PRIME is a program launched by the EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary program is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier. In addition, EMA has also granted an orphan drug designation for iptacopan in IgA nephropathy (IgAN).


About C3 glomerulopathy (C3G)
C3G is an ultra-rare and severe form of primary glomerulonephritis, characterized by complement dysregulation.1,9 It has a worldwide annual incidence of 1–2 per million11 and an approximate prevalence of 10,000 in the US, ~10,500 in Europe, 3,200 in Japan and 32,000 in China12.

C3G is commonly diagnosed in adolescents and young adults. The disease has a poor prognosis; about 50% of patient progress to end-stage renal disease (ESRD) within 10 years, and 50–70% experience disease recurrence post kidney transplant.2

Currently, there are no approved therapies specifically designed to target the underlying complement dysregulation that occurs in people with C3G. Current standard of care is with non-specific immunosuppressants with limited clinical evidence. Although antihypertensive or immunosuppressive agents and terminal complement pathway blockers are helpful in some patients, no treatment is universally effective or curative. 2,3,9,10 Therefore, novel treatment options are needed to address disease symptoms and slow the progression of C3G.

About iptacopan
Iptacopan (LNP023) is a first-in-class oral, small-molecule, reversible inhibitor of factor B, a key serine protease of the alternative pathway of the complement cascade.4,5

In addition to C3G, iptacopan is in parallel development for a number of other renal conditions with complement system involvement where significant unmet needs exist, including IgA nephropathy, atypical hemolytic uremic syndrome and membranous nephropathy.

Novartis is also investigating iptacopan in paroxysmal nocturnal hemoglobinuria (PNH). Following positive Phase II data presented at the European Society for Blood and Marrow Transplantation (EBMT) congress in August, a randomized, active-comparator controlled open-label Phase III trial (NCT04558918) to evaluate the efficacy and safety of iptacopan in PNH patients with residual anemia despite treatment with anti-C5 antibody therapy is planned to start in Dec 2020.13

Iptacopan has the potential to become the first alternative complement pathway inhibitor to slow disease progression in a number of complement driven diseases.

About the Study
The study (NCT03832114) is a Phase II, open-label, two cohort, non-randomized study evaluating the efficacy, safety and pharmacokinetics of iptacopan in patients with C3 glomerulopathy (C3G) (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).14 On completion of the study, patients can roll over into a long-term extension study (NCT03955445).

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. 

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at
https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References

1.Martín B and Smith R. C3 Glomerulopathy. [Last Update: April 5, 2018]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1425. Accessed September 2020.
2.Nester CM and Smith RJ. Treatment options for C3 glomerulopathy. CurrOpinNephrolHypertens. 2013;22(2):231–237.
3.Goodship TH, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539–551.
4.Merle NS, et al. Complement System Part II: Role in Immunity. Front Immunol. 2015;6:257.
5.Schubart A, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116(16):7926–7931.
6.Harris, C. L. Expanding horizons in complement drug discovery: challenges and emerging strategies. SeminImmunopathol. 2018;40(1):125–140.
7.Wong, E et al. LNP023, a novel, oral complement alternative pathway Factor B inhibitor, safely and effectively reduces proteinuria in C3 glomerulopathy. To be presented at the American Society of Nephrology Annual Meeting
8.Novartis. Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH). Available at: https://www.novartis.com/news/media-releases/novartis-announces-positive-results-from-phase-ii-study-lnp023-patients-paroxysmal-nocturnal-hemoglobinuria-pnh. Accessed September 2020.
9.Smith RJH, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129–143.
10.Mastellos DC, et al. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. SeminHematol. 2018;55(3):167–175.
11.Medjeral-Thomas NR, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014;9(1):46–53.
12.DRG Epidemiology Report, August 2019.
13.Novartis Data on File
14.ClinicalTrials.gov. Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted. Available at: https://clinicaltrials.gov/ct2/show/NCT03832114. Accessed September 2020.

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

Anja von Treskow
Novartis Global Media Relations
+41 61 324 2279 (direct)
+41 79 392 8697 (mobile)
anja.von_treskow@novartis.com




Eric Althoff
Novartis US External Communications
+1 646 438 4335
eric.althoff@novartis.com
Phil McNamara
Novartis Cardio-Metabolic Communications
+1 862 778 0218 (direct)
+1 862 274 5255 (mobile)
philip.mcnamara@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Thomas Hungerbuehler         +41 61 324 8425
Isabella Zinck +41 61 324 7188


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Stolt-Nielsen Limited to Host a Video Conference to Present the Results for the Second Quarter of 202118.6.2021 15:22:01 CEST | Press release

LONDON, June 18, 2021 – Stolt-Nielsen Limited (Oslo Børs: SNI) will host a video conference to present the Company’s unaudited results for the second quarter of 2021 on Thursday, July 1, 2021 at 15:00 CEST (09:00 EST, 14:00 BST). The presentation and video conference will be hosted by: - Mr. Niels G. Stolt-Nielsen - Chief Executive Officer, Stolt-Nielsen Limited - Mr. Jens F. Grüner-Hegge - Chief Financial Officer, Stolt-Nielsen Limited - Mr. Lucas Vos - President, Stolt Tankers Those who wish to watch the live broadcast may access it here The presentation will be published on our website: https://www.stolt-nielsen.com/en/investors/reports-presentations/ For additional information please contact: Jens F. Grüner-Hegge Chief Financial Officer UK +44 (0) 20 7611 8985 j.gruner-hegge@stolt.com Ellie Davison Head of Corporate Communications UK +44 (0) 20 7611 8926 e.davison@stolt.com About Stolt-Nielsen Limited Stolt-Nielsen Limited (SNL or 'the Company') is a long-term investor and manager

Hexagon Purus to supply hydrogen storage systems to KEYOU for internal combustion engine bus and truck projects in Europe18.6.2021 15:05:00 CEST | Press release

Hexagon Purus has received an order for hydrogen storage systems for KEYOU, a Munich, Germany-based clean mobility company. Hexagon Purus will supply hydrogen storage systems for KEYOU’s H2 combustion engine DEMO Bus with a leading European OEM and its DEMO truck project. Driving the energy transformation KEYOU has redesigned the traditional internal combustion engine enabling it to run on hydrogen as sustainable and clean fuel, bringing about a large leap in propulsion development. The company has succeeded in developing an emission-free, yet cost-effective hydrogen drive for commercial vehicles – without compromising performance, capacity or range. “KEYOU and Hexagon Purus share a common vision and a common interest – to drive the energy transition and achieve clean air everywhere,” says Michael Kleschinski, EVP Hexagon Purus. “As more European countries and cities announce strategic policies to promote the decarbonization of mobility, more commercial vehicles—especially city buses a

Hexagon Purus to supply hydrogen storage systems to KEYOU for internal combustion engine bus and truck projects in Europe18.6.2021 15:05:00 CEST | Press release

Hexagon Purus has received an order for hydrogen storage systems for KEYOU, a Munich, Germany-based clean mobility company. Hexagon Purus will supply hydrogen storage systems for KEYOU’s H2 combustion engine DEMO Bus with a leading European OEM and its DEMO truck project. Driving the energy transformation KEYOU has redesigned the traditional internal combustion engine enabling it to run on hydrogen as sustainable and clean fuel, bringing about a large leap in propulsion development. The company has succeeded in developing an emission-free, yet cost-effective hydrogen drive for commercial vehicles – without compromising performance, capacity or range. “KEYOU and Hexagon Purus share a common vision and a common interest – to drive the energy transition and achieve clean air everywhere,” says Michael Kleschinski, EVP Hexagon Purus. “As more European countries and cities announce strategic policies to promote the decarbonization of mobility, more commercial vehicles—especially city buses a

RESOLUTIONS of the Extraordinary General Meeting Of Shareholders of JSC “Olainfarm” held on June 18th, 202118.6.2021 14:45:00 CEST | Press release

RESOLUTIONS of the Extraordinary General Meeting Of Shareholders of JSC “Olainfarm” held on June 18th, 2021 1. Reports of the Management Board, Council and conclusion of certified auditor Resolution: To take a notice of reports of the Management Board, Council, Audit committee and conclusion of certified auditor of JSC “Olainfarm”. Voting results: the decision is taken with the required majority of votes. 2. Approval of Annual Report for year 2020 Resolution: To approve the Consolidated and Parent Company’s Annual Report of JSC „Olainfarm” for 2020 with profit in the amount of EUR 11 530 000,00. Voting results: the decision is taken with the required majority of votes. 3. Distribution of profit Resolution: 3.1. To pay dividends to the shareholders of the Joint Stock Company "Olainfarm" in the amount of EUR 2 394 463,26, which amounts to 0,17 euro (seventeen cents) per share, from accumulated before 31 December 2017 and not distributed profit. 3.2. Profit of JSC “Olainfarm” for the year

Wood Mackenzie Expands Energy Transition Expertise With Acquisition of Roskill18.6.2021 14:38:53 CEST | Press release

Niche integration deepens battery raw materials analysis EDINBURGH/LONDON, June 18, 2021 (GLOBE NEWSWIRE) -- Wood Mackenzie is pleased to announce its acquisition of Roskill,a privately-owned company and leader in metals and materials supply chain intelligence. Neal Anderson, President of Wood Mackenzie, commented: “Combining Roskill’s capabilities with Wood Mackenzie reinforces our ability to provide comprehensive, integrated analysis across the energy, and metals and mining value chain. In particular, Roskill adds market-leading analysis, data, and insight on battery raw materials metals, which are an integral component of the energy transition.” Wood Mackenzie, a Verisk business (Nasdaq:VRSK), also announced that Valerie Purvis has expanded her leadership remit and will be assuming the role of Global Head of Metals & Mining, including Roskill. This appointment is in addition to Valerie's current responsibility as Global Head of the Chemicals business, which she has successfully led

Prosafe SE and subsidiary company Prosafe Rigs Pte. Ltd. – Update on Financial Process18.6.2021 14:01:43 CEST | Press release

Reference is made to the earlier information provided about the ongoing financial process with the lenders, in particular to the press release on 27 May 2021 in which we gave notice that the High Court of Singapore had granted a 5 month moratorium protection to Prosafe SE and Prosafe Rigs Pte. Ltd (“PRPL"), in applications HC/OS 422/2021 and HC/OS 425/2021, in terms of Section 64 of the Insolvency, Restructuring and Dissolution Act 2018 ("the moratorium protection"). As at 18 June 2021, the Company has received acknowledgment of credit approval (subject to certain conditions) in support of the Transaction from ca. 96% across the USD 1300 million facility and the USD 144 million facility with additional credit approvals expected by end-June 2021. Following the grant of the moratorium protection, on 9 June 2021 petitions were presented to the Court of Session in Scotland seeking recognition, in Scotland, of the moratorium protection granted by the Singapore Court. In the petitions (P439/

Cleantech Building Materials: Results of Annual General Meeting18.6.2021 13:27:45 CEST | Press release

18 June 2021 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM Cleantech Building Materials plc Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 18 June 2021. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted on 25 May 2021 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion and 100% of the proxy votes cast were in favour of the resolutions. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Comp